<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20160307026950N47</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-12</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of Ondansetron on nausea and itching caused by spinal Fentanyl injection</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of prophylactic injection of doses of 4 and 8 mg of intravenous Ondansetron on nausea and itching after spinal injection of Fentanyl in spinal anesthesia, in lower limb orthopedic surgery</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/65640</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: This is a simple randomized clinical trial in which patients entered the study groups by lottery; The medicines and placebo are placed in sealed, opaque, and similar form packets coded. Each code is also written on a piece of paper, folded, and placed inside a box. After entering the operating room, each patient takes one of the papers out of the box; The pocket with the same number is the intervention that will apply to him. This process continues till the number of patients will reach the desired one, Blinding description: This is a three-way blind clinical trial; In this way, the researcher who records the patient's symptoms is different from the person who injects the drug and has no knowledge of the type of drug and is blind. The analysts who analyze the data collected during the study also don't know the type of intervention in any group and they are blind. Even though the patients are included in the study, they do not know the type of intervention and are blind.</study_design>
      <phase>3</phase>
      <hc_freetext>Spinal anesthesia.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group A: In this group of eligible patients, after receiving 5 ml/kg of Crystalloid fluid, they are placed on the surgical bed and cardiorespiratory monitoring is connected. Then they are subjected to spinal anesthesia with 25 μg of Fentanyl manufactured by Caspin Pharmaceutical Company and 12.5 mg of Markain manufactured by  Aburihan Pharmaceutical Company. Then 30 minutes after the spinal, they receive 8 mg of Ondansetron manufactured by Elixir pharmaceutical company intravenously. The patient's symptoms including blood pressure, heart rate, and breathing rate are checked and recorded regularly every 5 minutes for 15 minutes and then every 15 minutes until the end of the fourth hour. Intervention 2: Intervention group A: In this group of eligible patients, after receiving 5 ml/kg of Crystalloid fluid, they are placed on the surgical bed and cardiorespiratory monitoring is connected. Then they are subjected to spinal anesthesia with 25 μg of Fentanyl manufactured by Caspin Pharmaceutical Company and 12.5 mg of Markain manufactured by Aburihan Pharmaceutical Company. Then 30 minutes after the spinal, they receive 4 mg of Ondansetron manufactured by Elixir pharmaceutical company intravenously. The patient's symptoms including blood pressure, heart rate, and breathing rate are checked and recorded regularly every 5 minutes for 15 minutes and then every 15 minutes until the end of the fourth hour. Intervention 3: Control group C: In this group of eligible patients, after receiving 5 ml/kg of Crystalloid fluid, they are placed on the surgical bed and cardiorespiratory monitoring is connected. Then they are subjected to spinal anesthesia with 25 μg of Fentanyl manufactured by Caspin Pharmaceutical Company and 12.5 mg of Markain manufactured by  Aburihan Pharmaceutical Company. Then 30 minutes after the spinal, they receive 4 ml of distilled water manufactured by Elixir pharmaceutical company intravenously. The patient's symptoms including blood pressure, heart rate, and breathing rate are checked and recorded regularly every 5 minutes for 15 minutes and then every 15 minutes until the end of the fourth hour.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sepide Hasani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jarib</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8146713543</zip>
        <telephone>+98 31 3620 2020</telephone>
        <email>sepideh.hassani@yandex.com</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behzad Nazem roaya</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hezar Jarib</address>
        <city>Isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8146713543</zip>
        <telephone>+98 31 3620 2020</telephone>
        <email>behzad_nazem@med.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients 18 to 65 years old
Anesthesia class I and II according to ASA criteria
Candidate for lower limb surgery under spinal anesthesia
Informed consent to enter the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>History of smoking, drug and psychedelic addiction
Allergy to any anesthetic drugs, Ondansetron and fentanyl
History of coagulation disorders
High ICP
Pregnancy or breastfeeding
Skin infection at the injection site
Anti-nausea use in the last 24 hours</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group A: In this group of eligible patients, after receiving 5 ml/kg of Crystalloid fluid, they are placed on the surgical bed and cardiorespiratory monitoring is connected. Then they are subjected to spinal anesthesia with 25 μg of Fentanyl manufactured by Caspin Pharmaceutical Company and 12.5 mg of Markain manufactured by  Aburihan Pharmaceutical Company. Then 30 minutes after the spinal, they receive 8 mg of Ondansetron manufactured by Elixir pharmaceutical company intravenously. The patient's symptoms including blood pressure, heart rate, and breathing rate are checked and recorded regularly every 5 minutes for 15 minutes and then every 15 minutes until the end of the fourth hour.</i_keyword>
      <i_keyword>Intervention group A: In this group of eligible patients, after receiving 5 ml/kg of Crystalloid fluid, they are placed on the surgical bed and cardiorespiratory monitoring is connected. Then they are subjected to spinal anesthesia with 25 μg of Fentanyl manufactured by Caspin Pharmaceutical Company and 12.5 mg of Markain manufactured by Aburihan Pharmaceutical Company. Then 30 minutes after the spinal, they receive 4 mg of Ondansetron manufactured by Elixir pharmaceutical company intravenously. The patient's symptoms including blood pressure, heart rate, and breathing rate are checked and recorded regularly every 5 minutes for 15 minutes and then every 15 minutes until the end of the fourth hour.</i_keyword>
      <i_keyword>Control group C: In this group of eligible patients, after receiving 5 ml/kg of Crystalloid fluid, they are placed on the surgical bed and cardiorespiratory monitoring is connected. Then they are subjected to spinal anesthesia with 25 μg of Fentanyl manufactured by Caspin Pharmaceutical Company and 12.5 mg of Markain manufactured by  Aburihan Pharmaceutical Company. Then 30 minutes after the spinal, they receive 4 ml of distilled water manufactured by Elixir pharmaceutical company intravenously. The patient's symptoms including blood pressure, heart rate, and breathing rate are checked and recorded regularly every 5 minutes for 15 minutes and then every 15 minutes until the end of the fourth hour.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of nausea. Timepoint: Every 5 minutes after spinal until 15 minutes and then every 15 minutes until the end of the 4th hour. Method of measurement: Nausea and vomiting severity behavioral scale questionnaire.</prim_outcome>
      <prim_outcome>Itching scale. Timepoint: Every 5 minutes after spinal until 15 minutes and then every 15 minutes until the end of the 4th hour. Method of measurement: Itching severity scale questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-07-31</approval_date>
        <contact_name>Ethics Committee in Biomedical Research, Isfahan University of Medical Sciences</contact_name>
        <contact_address>Hezar Jarib Isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
